Molecular basis of influenza a virus sensitivity to commercial drugs : Screening for novel antiviral compounds /
الأسس الجزيئية لحساسية فيروسات الأنفلونزا إيه للعقاقير المتداولة : البحث عن مضادات فيروسات جديدة
Ola Muhamed Mansour Fathy Abdalla ; Supervised Hamdi Mahmoud Hassaneen , Mohammed Ahmed Ahmed Ali
- Cairo : Ola Muhamed Mansour Fathy Abdalla , 2016
- 119 P. : photographs ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Science - Department of Biotechnology
In Egypt, highly pathogenic avian influenza subtype H5NI virus (HPAIV/H5NI) was first reported in poultry in mid-february 2006 and declared to be endemic in 2008. The inadequate control measures enabled H5NI viruses to spread. Genetic drift in the virus was observed continuously each year and became more intense after 2008. Therefore, there is a necessity to develop new antiviral drugs targeting and eliminating the role of essential viral and cellular elements in the life cycle of the virus. The availability of drugs of different mode of actions would improve drug combination therapies to avoid the rapid emergence of drug-resistant viral strains. Despite, the re-emergence of amantadine-resistant HPAI H5NI and available reports about limited oseltamivir-resistant HPAI H5NI in Egypt which are based on theoretical sequence analysis of drug resistance markers, experimental studies to confirm the theoretical susceptibility of HPAI H5NI viruses to amantadine and oseltamivir are currently rare in Egypt
Influenza a virus sensitivity Molecular basis Novel antiviral compounds